VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

C4 Therapeutics Executive Compensation (FY25)

CCCC · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Andrew Hirsch
Latest say-on-pay support
=
June 24, 2026
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing

The C4 Therapeutics brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Get the executive briefGet the board briefNo account needed.
Data as of November 4, 2026Latest filing (8-K): June 24, 2026
8 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
C4 Therapeutics brief$500Get the executive brief
Velarion Intel, one year, every company
193 figures on this page: 188 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Andrew Hirsch: $5,239,784 → $2,940,975 (43.9% lower)
Say-on-pay support: 98.2% → 98.1% (0.1 points lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is C4 Therapeutics' chief executive and what were they paid?
Total compensation for Andrew Hirsch, President and Chief Executive Officer, came to $2,940,975 in fiscal 2025. Compared with the $5,239,784 reported for fiscal 2024, Hirsch's total was 43.9% lower.
What was C4 Therapeutics' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 98.1% of votes cast for or against in favor at the meeting held June 24, 2026.
Which companies are in C4 Therapeutics' peer group?
Companies named in the disclosed peer group include Adicet Bio, Inc., Arvinas, Inc., Black Diamond Therapeutics, Inc., Cullinan Therapeutics, Inc. and Editas Medicine, Inc., among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Stewart Fisher
Chief Scientific Officer
◇—◇◇◇—◇◇
Andrew Hirsch
President & Chief Executive Officer
◇—◇—◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Andrew Hirsch
President & Chief Executive Officer
◇—◇◇◇—◇◇
Leonard Reyno
Chief Medical Officer
◇◇◇◇◇—◇◇
Stewart Fisher
Chief Scientific Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Andrew Hirsch
President and Chief Executive Officer
◇—◇◇◇—◇◇
Leonard Reyno
Chief Medical Officer
◇—◇◇◇—◇◇
Kendra Adams
Chief Financial Officer and Head of Corporate Affairs
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Andrew Hirsch
President and Chief Executive Officer
◇◇◇◇◇—◇◇
Leonard Reyno
Chief Medical Officer
◇◇◇◇◇—◇◇
Kendra Adams
Chief Financial Officer and Head of Corporate Affairs
◇◇◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Andrew HirschRSU——————◇
Andrew HirschOption——————◇
Kendra AdamsRSU——————◇
Kendra AdamsOption——————◇
Leonard ReynoOption——————◇
Leonard ReynoRSU——————◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Andrew HirschOption◇—◇February 13, 2035
Option◇—◇February 13, 2034
RSU◇◇——
Option◇—◇February 14, 2033
RSU◇◇——
RSU◇◇——
Leonard ReynoOption◇—◇July 9, 2033
Option◇—◇February 13, 2035
Option◇—◇February 13, 2034
RSU◇◇——
RSU◇◇——
RSU◇◇——
Kendra AdamsOption◇—◇February 13, 2035
Option◇—◇February 13, 2034
RSU◇◇——
Option◇—◇September 17, 2033
RSU◇◇——
Option◇—◇February 12, 2033
RSU◇◇——
RSU◇◇——
Option◇—◇February 13, 2032
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Andrew Hirsch
President and Chief Executive Officer · Terms as described in the company’s compensation discussion
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇
Kendra Adams
Chief Financial Officer and Head of Corporate Affairs · Terms as described in the company’s compensation discussion
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇
Leonard Reyno
Chief Medical Officer · Terms as described in the company’s compensation discussion
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ronald Harold Wilfred Cooper
◇—◇———◇
Utpal Koppikar
◇—◇———◇
Donna Grogan
◇—◇———◇
Stephen Hoerter
◇—◇———◇
Laura Bessen
◇—◇———◇
Owen P. Hughes Jr
◇—◇———◇
Kenneth C. Anderson
◇—◇———◇
Stephen Fawell
◇—◇———◇
Bruce Downey
◇—————◇
Andrew J. Hirsch served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Adicet Bio, Inc. ACET
  • Arvinas, Inc. ARVN
  • Black Diamond Therapeutics, Inc. BDTX
  • Cullinan Therapeutics, Inc. CGEM
  • Editas Medicine, Inc. EDIT
  • Foghorn Therapeutics Inc. FHTX
  • Fulcrum Therapeutics, Inc. FULC
  • IGM Biosciences, Inc. IGMS
  • iTeos Therapeutics, Inc. ITOS
  • Kymera Therapeutics, Inc. KYMR
  • Lyell Immunopharma, Inc. LYEL
  • Monte Rosa Therapeutics, Inc. GLUE
  • Nkarta, Inc. NKTX
  • Nurix Therapeutics, Inc. NRIX
  • ORIC Pharmaceuticals, Inc. ORIC
  • Poseida Therapeutics, Inc. PSTX
  • Prelude Therapeutics Incorporated PRLD
  • Relay Therapeutics, Inc. RLAY
  • Sutro Biopharma, Inc. STRO
  • Tango Therapeutics, Inc. TNGX

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 24, 2026=◇◇◇
2024June 18, 2025=◇◇◇
2023June 20, 2024=◇◇◇
2022June 15, 2023=◇◇◇
2021June 22, 2022=◇◇◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Andrew Hirsch (President and Chief Executive Officer), FY2025 total compensation $2,940,975 (base salary $694,925) [exec_comp, SEC accession 0001628280-26-028104, filed 2026-04-29]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when C4 Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact C4 Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where C4 Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether C4 Therapeutics' disclosed peer group is defensible, who names C4 Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
193 figures on this page: 188 cited to the filing that reported them, 5 calculated from figures it prints.
188 cited to the filing
5 calculated from the filing

Documents cited

  1. 0001628280-26-045194
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001628280-26-028104
    Compensation Discussion and Analysis · Director Compensation · Summary Compensation Table
  3. 0001628280-25-032155
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001628280-25-020466
    Summary Compensation Table
  5. 0001628280-24-029301
  6. 0001628280-24-018785
  7. 0001628280-23-022597
  8. 0001564590-22-024179
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “C4 Therapeutics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/CCCC (accessed 2026).
Short form: data: Velarion

The C4 Therapeutics brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Get the executive briefGet the board briefNo account needed.
8 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about C4 Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers C4 Therapeutics discloses

The companies named in CCCC's own disclosed peer group.

Adicet Bio, Inc.Arvinas, Inc.Black Diamond Therapeutics, Inc.Cullinan Therapeutics, Inc.Editas Medicine, Inc.Foghorn Therapeutics Inc.Fulcrum Therapeutics, Inc.IGM Biosciences, Inc.iTeos Therapeutics, Inc.Kymera Therapeutics, Inc.Lyell Immunopharma, Inc.Monte Rosa Therapeutics, Inc.Nkarta, Inc.Nurix Therapeutics, Inc.ORIC Pharmaceuticals, Inc.Poseida Therapeutics, Inc.Prelude Therapeutics IncorporatedRelay Therapeutics, Inc.Sutro Biopharma, Inc.Tango Therapeutics, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy